Emperor International Holdings (00928.HK) establishes joint ventures to expand into the healthcare industry.

The Zhixun Finance APP reported that Emperor International Investment (00928.HK) announced that on July 7, 2025, the company or its designated subsidiaries, Ankelo (Shenzhen) Synthetic Biology Industrial Development Co., Ltd. (Ankelo Synthetic), Ankelo (Shenzhen) Biotechnology Co., Ltd. (Ankelo Biotechnology), Shenzhen Super Oxygen Epoch Biotechnology Co., Ltd. (Shenzhen Super Oxygen), and Wang Xiaofeng (joint venture partner) have established a joint venture in China. The joint venture is owned 34% by the company and 63% by the joint venture partner. The company and the joint venture partner have contributed HK$3.4 million and HK$6.3 million in cash or assets to the joint venture in proportion to their respective shareholdings. As of the date of this announcement, the Group expects no further capital injection commitment to the joint venture. The joint venture will be accounted for as an investment in associates in the Group's consolidated financial statements.